Ebola vaccines race: 3 fast‑tracked candidates and their timeline

Amid a sudden surge of the Bundibugyo strain, scientists are racing to deliver the first approved Ebola vaccines for this variant.

Ebola vaccines: development timeline

Three experimental platforms – a viral‑vector, a recombinant protein and a nucleic‑acid formulation – have been placed on accelerated pathways, ↑ 3 candidates now in Phase II trials. Regulatory agencies in the Democratic Republic of Congo and the WHO are coordinating fast‑track reviews, hoping to compress the usual 12‑month schedule to under six months. Manufacturing capacity is being scaled in Europe and the United States, but supply‑chain bottlenecks could shave ↓ 30% of projected doses. A senior WHO official warned,

“We cannot afford delays; the window to curb transmission is narrowing.”

The first batch could reach frontline clinics by early 2027, according to Reuters. Meanwhile, community outreach teams are reminded of lessons from the recent pandemic that highlighted the importance of trust. For deeper insight, see the latest report from AP News.